Cardiovascular Health

New results from the phase 3 HYPERION trial demonstrate reduced risks as early as the year following diagnosis of pulmonary arterial hypertension.

The RNA interference therapy indicated that, along with its therapeutic benefits in cardiomyopathy transthyretin-mediated amyloidosis (ATTR-CM), there was a reduced risk of GI events.

Individuals with heart failure who are Black, Hispanic, or Asian face a much earlier onset of heart failure hospitalization compared with White patients.

Fluctuations in glycemic delta, a specific measurement of glucose levels, is an indicator of worsened myocardial infarction outcomes, including greater reductions in left ventricular ejection fraction.

Digitoxin reduces primary composite vs placebo in HFrEF, with no statistically significant effect on individual components of all-cause mortality or first heart failure-related hospitalization.

Bumetanide nasal spray provides patients with edema an alternative to burdensome oral or intravenous diuretic options.

Pharmacists enhance patient safety by addressing common medication errors, ensuring proper drug use, and improving therapeutic outcomes in clinical practice.

Investigators emphasize that early cardiovascular risk assessments and preventive strategies are necessary for women with polycystic ovarian syndrome (PCOS).

The trial results, which showed baxdrostat significantly reduced mean seated systolic blood pressure in uncontrolled hypertension, were presented at the 2025 European Society of Cardiology Congress.

GLP-1 medications like semaglutide and tirzepatide significantly lower heart failure hospitalization risks, expanding treatment options for obesity-related conditions.

Reduced-dose apixaban maintains efficacy with less bleeding for extended CAT prophylaxis, reinforcing NCCN’s preexisting guidance in intermediate to high-risk cancer patients.

New research reveals that women on beta-blockers post-heart attack face a 45% higher risk of serious health issues compared with men.

Young adults who had experienced an acute myocardial infarction and lived in marginalized communities had increased risks of adverse events and reduced visits to their physician or cardiologist.

Increasing dietary potassium, such as from bananas, may lower blood pressure more effectively than reducing sodium alone.

Evolocumab is now indicated for adults at increased risk for major adverse cardiovascular events (MACE).

The recombinant shingles vaccine not only reduces herpes zoster and herpes zoster ophthalmicus but is also associated with lower risks of hospitalization for stroke and myocardial infarction in adults aged 50 and older.

Individuals with bipolar disorder are at nearly a 2-fold higher risk of heart failure, which is marked as the main cause of premature cardiovascular mortality.

Individuals with cognitive and physical disabilities faced difficulties in health care utilization and had reduced rates of preventive cardiovascular screenings during the pandemic.

FDA approves a new liquid formulation of losartan for hypertension treatment, enhancing accessibility for adults and children over 6 years old.

Aficamten offers new hope for HCM patients, showing significant clinical benefits and safety in recent trials, enhancing treatment options.

In children and adolescents with overweight and obesity, exercise was demonstrated to reduce risk factors associated with cardiovascular disease, such as lipid and triglyceride levels.

Discover effective strategies for managing obesity to enhance cardiovascular health, including innovative treatments and the vital role of pharmacists.

Promoting heart health in children reduces obesity and chronic disease risks, ensuring better overall well-being into adulthood.

In the SURPASS-CVOT clinical trial, tirzepatide was non-inferior to dulaglutide in a composite score of cardiovascular outcomes in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD).